CD33 Delineates Two Functionally Distinct NK Cell Populations Divergent in Cytokine Production and Antibody-Mediated Cellular Cytotoxicity.
Antibody-Dependent Cell Cytotoxicity
/ immunology
CD56 Antigen
/ immunology
Cells, Cultured
Cytokines
/ immunology
Cytotoxicity, Immunologic
/ immunology
Flow Cytometry
/ methods
Gene Expression Profiling
/ methods
Humans
K562 Cells
Killer Cells, Natural
/ immunology
Proto-Oncogene Proteins c-kit
/ genetics
Receptors, Chimeric Antigen
/ immunology
Receptors, IgG
/ genetics
Sialic Acid Binding Ig-like Lectin 3
/ genetics
Up-Regulation
CD33-CAR
NK cell
NK cell expansion
RNAseq analysis
cytokine production and cytotoxicity
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2021
2021
Historique:
received:
19
10
2021
accepted:
29
11
2021
entrez:
21
1
2022
pubmed:
22
1
2022
medline:
1
3
2022
Statut:
epublish
Résumé
The generation and expansion of functionally competent NK cells
Identifiants
pubmed: 35058934
doi: 10.3389/fimmu.2021.798087
pmc: PMC8764454
doi:
Substances chimiques
CD56 Antigen
0
Cytokines
0
NCAM1 protein, human
0
Receptors, Chimeric Antigen
0
Receptors, IgG
0
Sialic Acid Binding Ig-like Lectin 3
0
Proto-Oncogene Proteins c-kit
EC 2.7.10.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
798087Informations de copyright
Copyright © 2022 Hejazi, Zhang, Bennstein, Balz, Reusing, Quadflieg, Hoerster, Heinrichs, Hanenberg, Oberbeck, Nitsche, Cramer, Pfeifer, Oberoi, Rühl, Oldenburg, Brossart, Horn, Babor, Wels, Fischer, Möker and Uhrberg.
Déclaration de conflit d'intérêts
CZ, MQ, MN, SC, RP, and NM are employees of Miltenyi Biotec. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Immunol Lett. 1993 Aug;37(2-3):223-8
pubmed: 7505004
J Hematol Oncol. 2017 Jul 25;10(1):142
pubmed: 28743264
Cell. 2018 Aug 23;174(5):1054-1066
pubmed: 30142344
Haematologica. 2015 May;100(5):643-52
pubmed: 25682594
EMBO J. 2014 Nov 18;33(22):2721-34
pubmed: 25319415
Immunol Rev. 2015 Sep;267(1):178-96
pubmed: 26284478
Blood. 2008 Aug 1;112(3):461-9
pubmed: 18650461
Cancer Immunol Immunother. 2021 Dec;70(12):3701-3708
pubmed: 34398302
Sci Rep. 2017 Mar 21;7(1):270
pubmed: 28325905
Immunol Rev. 2008 Aug;224:98-123
pubmed: 18759923
Cancer Res. 2009 May 1;69(9):4010-7
pubmed: 19383914
Front Immunol. 2019 Aug 22;10:2001
pubmed: 31507603
Blood. 2010 Nov 11;116(19):3853-64
pubmed: 20696944
J Immunol Res. 2019 Apr 15;2019:6032141
pubmed: 31143782
Nat Rev Immunol. 2007 Apr;7(4):255-66
pubmed: 17380156
J Immunol. 2016 Apr 1;196(7):2923-31
pubmed: 26994304
J Clin Oncol. 2017 Aug 10;35(23):2674-2682
pubmed: 28644774
Blood Adv. 2020 Nov 24;4(22):5868-5876
pubmed: 33232480
N Engl J Med. 2020 Feb 6;382(6):545-553
pubmed: 32023374
Blood. 2014 Aug 21;124(8):1221-31
pubmed: 24951430
Elife. 2020 Jul 13;9:
pubmed: 32657756
Cancer Immunol Immunother. 2011 Dec;60(12):1683-95
pubmed: 21706285
Future Oncol. 2021 Jan;17(3):263-277
pubmed: 33356566
Blood. 2013 May 2;121(18):3599-608
pubmed: 23487023
Stem Cells Transl Med. 2021 Jun;10(6):867-882
pubmed: 33475258
Cells. 2020 Mar 27;9(4):
pubmed: 32230942
Immunity. 2017 Nov 21;47(5):820-833
pubmed: 29166586
Leukemia. 2015 Aug;29(8):1637-47
pubmed: 25721896
Blood Adv. 2018 Jun 26;2(12):1459-1469
pubmed: 29941459